Larimar Therapeutics, Inc. (LRMR)Healthcare | Biotechnology | Bala Cynwyd, United States | NasdaqGM
3.72 USD
-0.01
(-0.134%) ⇩
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:21 a.m. EDT
The investment case here is fundamentally broken despite the recent catalyst of a director purchase and analyst upgrades. The company is burning cash aggressively with negative free cash flow and operating cash flow, while returning equity to shareholders via buybacks—a dangerous combination for a biotech firm with no revenue. The balance sheet is fragile, holding only about $200 million in cash against a market cap of $445 million, leaving a runway that is precarious given the burn rate. While the stock has rallied recently, the long-term trajectory over the last decade shows a catastrophic -96% decline, reflecting the market's deep skepticism about the business model's ability to generate sustainable value. The recent surge is likely driven by specific clinical data hopes rather than a turnaround in fundamentals. For investors, the lack of dividends and the high risk of capital erosion make this a poor long-term hold. Short-term, the heavy put option positioning suggests traders are bracing for a sharp correction if the latest clinical results do not meet lofty expectations, making the current price a risky entry point for momentum plays. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.114294 |
| MSTL | 0.155181 |
| AutoETS | 0.159992 |
| AutoARIMA | 0.159995 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.88 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.123 |
| Excess Kurtosis | 0.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.391 |
| Market Cap | 386,444,512 |
| Forward P/E | -3.15 |
| Beta | 0.84 |
| Website | https://www.larimartx.com |
As of July 11, 2026, 4:21 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts expiring in August and December at the $2.50 strike. This creates a significant 'put wall' that suggests a fear of a drop to that level. Conversely, call activity is concentrated in the money ($5.00) and moderately out-of-the-money ($7.50), indicating some speculative bets on a rebound to the $7.50 zone, but the sheer volume of put buying dominates the sentiment profile.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.17879748 |
| Address1 | Three Bala Plaza East |
| Address2 | Suite 506 |
| All Time High | 664.32 |
| All Time Low | 1.53 |
| Ask | 4.65 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 3,680,420 |
| Average Daily Volume3 Month | 2,195,778 |
| Average Volume | 2,195,778 |
| Average Volume10Days | 3,680,420 |
| Beta | 0.837 |
| Bid | 2.69 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.514 |
| City | Bala Cynwyd |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.72 |
| Current Ratio | 4.292 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.8177 |
| Day Low | 3.58 |
| Debt To Equity | 2.391 |
| Display Name | Larimar Therapeutics |
| Dividend Date | 1,590,710,400 |
| Earnings Timestamp | 1,778,761,800 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -172,100,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.114 |
| Enterprise Value | 191,699,520 |
| Eps Current Year | -1.60739 |
| Eps Forward | -1.17962 |
| Eps Trailing Twelve Months | -2.12 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.6053 |
| Fifty Day Average Change | 0.11470008 |
| Fifty Day Average Change Percent | 0.031814296 |
| Fifty Two Week Change Percent | 17.87975 |
| Fifty Two Week High | 6.42 |
| Fifty Two Week High Change | -2.7 |
| Fifty Two Week High Change Percent | -0.42056075 |
| Fifty Two Week Low | 2.715 |
| Fifty Two Week Low Change | 1.0050001 |
| Fifty Two Week Low Change Percent | 0.3701658 |
| Fifty Two Week Range | 2.715 - 6.42 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,403,184,600,000 |
| Float Shares | 59,939,814 |
| Forward Eps | -1.17962 |
| Forward P E | -3.1535578 |
| Free Cashflow | -71,305,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 71 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.011460001 |
| Held Percent Institutions | 0.86057997 |
| Implied Shares Outstanding | 103,882,937 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania. |
| Long Name | Larimar Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 386,444,512 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_572350487 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -166,004,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 386,963,940 |
| Number Of Analyst Opinions | 10 |
| Open | 3.74 |
| Operating Cashflow | -131,275,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 844 511 9056 |
| Pre Market Change | 0.03999996 |
| Pre Market Change Percent | 1.0752678 |
| Pre Market Price | 3.76 |
| Pre Market Time | 1,784,111,696 |
| Previous Close | 3.7250001 |
| Price Eps Current Year | -2.3143108 |
| Price Hint | 4 |
| Price To Book | 2.4570673 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.212 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.18182 |
| Region | US |
| Regular Market Change | -0.00500011 |
| Regular Market Change Percent | -0.134231 |
| Regular Market Day High | 3.8177 |
| Regular Market Day Low | 3.58 |
| Regular Market Day Range | 3.58 - 3.8177 |
| Regular Market Open | 3.74 |
| Regular Market Previous Close | 3.7250001 |
| Regular Market Price | 3.72 |
| Regular Market Time | 1,784,059,201 |
| Regular Market Volume | 1,842,120 |
| Return On Assets | -0.56916 |
| Return On Equity | -1.09827 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 103,882,937 |
| Shares Percent Shares Out | 0.1174 |
| Shares Short | 12,193,251 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 8,046,494 |
| Short Name | Larimar Therapeutics, Inc. |
| Short Percent Of Float | 0.18129998 |
| Short Ratio | 4.09 |
| Source Interval | 15 |
| State | PA |
| Symbol | LRMR |
| Target High Price | 26.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 14.4 |
| Target Median Price | 12.5 |
| Total Cash | 200,384,992 |
| Total Cash Per Share | 1.92 |
| Total Debt | 3,779,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.947425 |
| Two Hundred Day Average Change | -0.22742486 |
| Two Hundred Day Average Change Percent | -0.057613473 |
| Type Disp | Equity |
| Volume | 1,842,120 |
| Website | https://www.larimartx.com |
| Zip | 19,004 |